Ascletis doses first participants in obesity drug study

Ascletis Pharma Inc. announced the first participants with obesity or overweight and at least one weight-related comorbidity have been dosed in its U.S. 12-week Phase IIa study for ASC30.

The study evaluates a once-monthly subcutaneous depot formulation of the small molecule GLP-1R agonist. The ultra-long-acting formulation demonstrated a 36-day half-life in a Phase Ib study, supporting once-monthly administration.

Topline data for the Phase IIa study are anticipated in the first quarter of 2026.